

In the Claims

Listing of the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

Claims 1-16 (Canceled)

17. (New) A method of treating a human or animal suffering from the effects of infection with *Yersinia pestis*, comprising administering to the human or animal, a therapeutically effective amount of a medicament comprising an antibody specific for *Yersinia pestis* F1-antigen, or a binding fragment thereof, or an antibody specific for *Yersinia pestis* V-antigen, or a binding fragment thereof, or a combination thereof.

18. (New) The method of claim 17, wherein the antibodies are monoclonal antibodies.

19. (New) The method of claim 17, wherein the medicament is for administration up to about 48 hours post-infection.

20. (New) The method of claim 17, wherein the antibody specific for *Yersinia pestis* V-antigen or binding fragment thereof specifically binds an epitope of the V-antigen found between amino acids 135-275 of the sequence of the V-antigen.

21. (New) The method of claim 17, wherein the antibodies, or binding fragments thereof, are humanised.

22. (New) The method of claim 17, wherein the method comprises administering a combination of an antibody specific for *Yersinia pestis* F1-antigen and an antibody specific for *Yersinia pestis* V-antigen.

23. (New) The method of claim 17, wherein the antibody specific for *Yersinia pestis* V-antigen or binding fragment thereof specifically binds an epitope of the V-antigen found between amino acids 1-275 of the sequence of the V-antigen.

24. (New) The method of claim 17, wherein the medicament is administered in a form suitable for oral use, for administration by inhalation, for administration by insufflation or for parental administration.

25. (New) A pharmaceutical composition comprising an antibody specific for *Yersinia pestis* V-antigen or a binding fragment thereof, an antibody specific for *Yersinia pestis* F1-antigen or a binding fragment thereof and a pharmaceutically acceptable carrier.

26. (New) The pharmaceutical composition of claim 25, wherein the antibodies are monoclonal antibodies.

27. (New) The pharmaceutical composition of claim 25, wherein the antibody specific for *Yersinia pestis* V-antigen or binding fragment thereof specifically binds an epitope of the V-antigen found between amino acids 135-275 of the sequence of the V-antigen.

28. (New) The pharmaceutical composition of claim 25, wherein the antibodies or binding fragments thereof, are humanised or fully human.

29. (New) A prophylactic vaccine for protection of a human or animal against infection by *Yersinia pestis*, comprising the composition of claim 25.
30. (New) A method of immunising against infection by *Yersinia pestis* comprising administering the vaccine of claim 29.
31. (New) The pharmaceutical composition of claim 25, wherein the antibody specific for *Yersinia pestis* V-antigen or binding fragment thereof specifically binds an epitope of the V-antigen found between amino acids 1-275 of the sequence of the V-antigen.
32. (New) The method of claim 30, wherein the vaccine is administered in a form suitable for oral use, for administration by inhalation, for administration by insufflation or for parental administration.